Faron Pharmaceuticals Oy (FARN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Faron Pharmaceuticals Oy (FARN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8072
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フィンランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that conducts clinical stage drug discovery and development. The company’s pipeline products focus on cute organ traumas, vascular damage and cancer immunotherapy. It offers Traumakine, that helps to prevent vascular leakage and organ failures and is the only treatment for acute respiratory distress syndrome (ARDS). Faron’s Clevegen is a pre-clinical anti-Clever-1 antibody that has the ability to switch immune suppression to immune activation in various conditions. The company’s Clevegen can be used for oncology, infectious disease and vaccine development. It partners with academic institutions and pharmaceutical companies. Faron is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Faron Pharmaceuticals Oy, Medical Devices Deals, 2012 to YTD 2018 9
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Faron Pharma Enters into Agreement with University of Birmingham Medical School 12
Faron Pharma Enters into Agreement with Selexis 13
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 14
Licensing Agreements 15
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 15
China Medical System Enters into Licensing Agreement with Faron Pharma 16
Equity Offering 17
Faron Pharma Raises USD10 Million in Second Tranche of Private Placement of Shares 17
Faron Pharma Raises USD0.5 Million in Second Tranche of Rights Offering of Shares 19
Faron Pharma Raises USD13.3 Million in Private Placement of Shares 20
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 21
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 22
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 23
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 24
Faron Pharma Raises USD6 Million in Private Placement of Shares 25
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 26
Faron Pharma Raises Funds in IPO 28
Acquisition 29
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 29
Faron Pharmaceuticals Oy – Key Competitors 30
Faron Pharmaceuticals Oy – Key Employees 31
Faron Pharmaceuticals Oy – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Sep 13, 2018: Faron Pharmaceuticals: Interim results for the six months ended 30 June 2018 33
May 08, 2018: Faron Pharmaceuticals: Final Results for the year ended 31 December 2017 38
Sep 06, 2017: Faron Pharmaceuticals: Interim Results for the six months ended 30 June 2017 39
Mar 29, 2017: Faron Pharmaceuticals: Final Results for the year ended 31 December 2016 40
Feb 09, 2017: Faron update for 2017 46
Corporate Communications 47
Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 47
Apr 19, 2017: Faron Pharmaceuticals: Proposed Board Changes 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Faron Pharmaceuticals Oy, Deals By Therapy Area, 2012 to YTD 2018 8
Faron Pharmaceuticals Oy, Medical Devices Deals, 2012 to YTD 2018 9
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Faron Pharma Enters into Agreement with University of Birmingham Medical School 12
Faron Pharma Enters into Agreement with Selexis 13
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 14
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 15
China Medical System Enters into Licensing Agreement with Faron Pharma 16
Faron Pharma Raises USD10 Million in Second Tranche of Private Placement of Shares 17
Faron Pharma Raises USD0.5 Million in Second Tranche of Rights Offering of Shares 19
Faron Pharma Raises USD13.3 Million in Private Placement of Shares 20
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 21
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 22
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 23
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 24
Faron Pharma Raises USD6 Million in Private Placement of Shares 25
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 26
Faron Pharma Raises Funds in IPO 28
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 29
Faron Pharmaceuticals Oy, Key Competitors 30
Faron Pharmaceuticals Oy, Key Employees 31

List of Figures
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Faron Pharmaceuticals Oy, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Faron Pharmaceuticals Oy (FARN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • icapital biz Berhad:企業の戦略・SWOT・財務情報
    icapital biz Berhad - Strategy, SWOT and Corporate Finance Report Summary icapital biz Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • S Group:企業の戦略的SWOT分析
    S Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Telekom Malaysia Berhad:企業の戦略・SWOT・財務情報
    Telekom Malaysia Berhad - Strategy, SWOT and Corporate Finance Report Summary Telekom Malaysia Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Fives:企業の戦略・SWOT・財務情報
    Fives - Strategy, SWOT and Corporate Finance Report Summary Fives - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • Reply SpA (REY):企業の財務・戦略的SWOT分析
    Reply SpA (REY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Cytogel Pharma LLC-製薬・医療分野:企業M&A・提携分析
    Summary Cytogel Pharma LLC (Cytogel Pharma) is a biopharmaceutical development company that provides platform technologies and product candidates. The company offers novel analgesic product candidates and polymer and hydrogel drug delivery platform technologies. Its analgesic product candidates offe …
  • Stryker Corp (SYK):医療機器:M&Aディール及び事業提携情報
    Summary Stryker Corp (Stryker) is a medical technology company that manufactures an array of orthopaedic, medical and surgical, and neurotechnology and spine products and allied services. Its major products include orthopaedic implants; surgical equipment and surgical navigation systems; patient han …
  • Investimentos, Participacoes e Gestao SA (INA):企業の財務・戦略的SWOT分析
    Investimentos, Participacoes e Gestao SA (INA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • China Environmental Energy Investment Limited:企業のM&A・事業提携・投資動向
    China Environmental Energy Investment Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Environmental Energy Investment Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, …
  • Medifocus Inc (MFS):医療機器:M&Aディール及び事業提携情報
    Summary Medifocus Inc (Medifocus) is a medical technology company. The company develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate. Its technology platforms includes endo-thermotherapy platform, a catheter-based …
  • NeuroSearch AS (NEUR)-製薬・医療分野:企業M&A・提携分析
    Summary NeuroSearch A/S (NeuroSearch) focuses on the development of novel pharmaceutical agents for the treatment of various disorders of central nervous system (CNS) through license agreements with other life science companies. The company divested all rights of Huntexil for the treatment of patien …
  • Beautiful Brands International, LLC:企業の戦略・SWOT・財務分析
    Beautiful Brands International, LLC - Strategy, SWOT and Corporate Finance Report Summary Beautiful Brands International, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Univalor Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Univalor Inc (Univalor) is a university technology transfer organization that optimizes research outcomes by commercializing the technological innovations of researchers from health centers and academic institutions. The organization provides researcher services such as protecting intellectu …
  • Mr. Price Group Ltd.
    Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pernod Ricard SA (RI):企業の財務・戦略的SWOT分析
    Pernod Ricard SA (RI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Daktronics Inc (DAKT):企業の財務・戦略的SWOT分析
    Daktronics Inc (DAKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ViroGates AS:医療機器:M&Aディール及び事業提携情報
    Summary ViroGates AS (ViroGates) is a meditech company that offers prognostic products. The company develops a prognostic biomarker to make the suPAR test presented as a commercially available test. Its products comprise measures suPAR, quick triage and ELISA. ViroGates’ suparnostic products offer a …
  • Woolworths Holdings Limited:戦略・SWOT・企業財務分析
    Woolworths Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Woolworths Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Laerdal Medical AS:企業の戦略的SWOT分析
    Laerdal Medical AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Blue Moon Zinc Corp.:企業の戦略・SWOT・財務情報
    Blue Moon Zinc Corp. - Strategy, SWOT and Corporate Finance Report Summary Blue Moon Zinc Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆